vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and OnKure Therapeutics, Inc. (OKUR). Click either name above to swap in a different company.
OnKure Therapeutics, Inc. is the larger business by last-quarter revenue ($802.0K vs $410.0K, roughly 2.0× Solowin Holdings, Ltd.). Solowin Holdings, Ltd. produced more free cash flow last quarter ($-1.6M vs $-13.0M).
OnKure Therapeutics, Inc. is a clinical-stage biotechnology company specializing in precision oncology therapy development. It focuses on creating targeted small molecule drugs including epigenetic and kinase inhibitors, to address unmet medical needs for patients with hard-to-treat solid tumors and hematologic cancers, serving global oncology patient segments.
AXG vs OKUR — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $802.0K |
| Net Profit | — | $-14.7M |
| Gross Margin | — | — |
| Operating Margin | -34.1% | -1932.8% |
| Net Margin | — | -1832.8% |
| Revenue YoY | — | 1922.7% |
| Net Profit YoY | — | -27.2% |
| EPS (diluted) | — | $-1.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $802.0K | ||
| Q2 25 | — | $934.0K | ||
| Q3 24 | $410.0K | $-44.0K |
| Q3 25 | — | $-14.7M | ||
| Q2 25 | — | $-15.4M | ||
| Q3 24 | — | $-11.6M |
| Q3 25 | — | -1932.8% | ||
| Q2 25 | — | -1747.8% | ||
| Q3 24 | -34.1% | 26163.6% |
| Q3 25 | — | -1832.8% | ||
| Q2 25 | — | -1647.8% | ||
| Q3 24 | — | 26263.6% |
| Q3 25 | — | $-1.09 | ||
| Q2 25 | — | $-1.14 | ||
| Q3 24 | — | $-36.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $70.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.0M | $66.4M |
| Total Assets | $13.1M | $72.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $70.3M | ||
| Q2 25 | — | $83.4M | ||
| Q3 24 | $2.5M | $76.7M |
| Q3 25 | — | $66.4M | ||
| Q2 25 | — | $78.2M | ||
| Q3 24 | $6.0M | $-135.1M |
| Q3 25 | — | $72.8M | ||
| Q2 25 | — | $86.1M | ||
| Q3 24 | $13.1M | $77.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-13.0M |
| Free Cash FlowOCF − Capex | $-1.6M | $-13.0M |
| FCF MarginFCF / Revenue | -392.9% | -1626.3% |
| Capex IntensityCapex / Revenue | 4.4% | 0.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-13.0M | ||
| Q2 25 | — | $-13.3M | ||
| Q3 24 | $-1.6M | $-10.7M |
| Q3 25 | — | $-13.0M | ||
| Q2 25 | — | $-13.3M | ||
| Q3 24 | $-1.6M | $-10.7M |
| Q3 25 | — | -1626.3% | ||
| Q2 25 | — | -1422.6% | ||
| Q3 24 | -392.9% | 24270.5% |
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 1.4% | ||
| Q3 24 | 4.4% | -40.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
